ArticleFrontiers in medicine2025
Relationship between serum cystatin C and diabetic retinopathy in T2DM patients.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cystatin C (CysC), as a crucial and sensitive indicator for renal function, has gradually drawn attention for its role in diabetic complications. This study aims to investigate the association between serum CysC levels and diabetic retinopathy (DR). Method: This cross-sectional study enrolled 818 individuals with type 2 diabetes, including 227 DR patients and 591 patients without DR. All subjects underwent detailed clinical evaluations, including blood glucose, lipid, renal function indicators, and fundus examinations. Logistic regression analyses were applied to assess the correlation between CysC and DR. Results: The serum CysC levels in DR patients was significantly higher than those of the controls ( Conclusion: Patients with higher serum CysC levels have an elevated risk of DR in the T2DM population. Future large-scale studies should explore the potential mechanism of CysC in DR and evaluate its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.